Transformingcare.

A different approach to research aimed at improving patient outcomes at the point of care. This is what ObjectiveGI is all about.

 

PHYSICIANS

Transforming Your Capabilities.

We provide the seamless integration of GI research into your practice to broaden your offerings, enhance care for your patients, and increase your support for referring physicians.

Learn More

SPONSORS

Transforming Your Research.

With premier integrated research partnerships across the country, we can offer a program supported by embedded study teams, leading to greater patient access at the point of care.

Learn More
 
 

PATIENTS

Transforming Your Outlook.

We are studying NASH and other diseases with the aim of developing new therapies to address growing problems and improve your overall health.

Learn More

Let’s work together.

We’re taking on NASH with strong research partnerships and innovative approaches that leverage a proven platform. You can be part of it.

Our Approach

Featured news

 

Studies show microbiome may contribute to all immune-related diseases

Multiple studies suggest that the gut microbiome likely contributes to all diseases caused by a dysregulation of the immune system – including obesity, diabetes, and NASH.

 

New ADA Recommendation

The American Diabetes Association is now recommending screening for liver fibrosis in patients with type 2 diabetes suspected of having nonalcoholic fatty liver disease.

 

Weight loss continues to be associated with clinically meaningful improvements

Weight loss continues to be associated with clinically meaningful improvements in biomarkers of nonalcoholic fatty liver disease.

 

New research aimed at developing a first-in-class dual agonist

New research aimed at developing a first-in-class dual agonist that targets all three key drivers of NASH – steatosis, inflammation, and fibrosis.